Efficacy and safety of novel NK-1 antagonist, Fosaprepitant for the prevention of CINV

Efficacy and safety of novel NK-1 antagonist, Fosaprepitant for the prevention of CINV - Efficacy and safety of Fosaprepitant for the prevention of CINV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007376

Enrollment

100

Registered

2012-03-01

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients receiving highly or moderately emetogenic agents

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Adult 2)Patients receiving highly or moderately emetogenic agents 3)A consent form for participating in this study is submitted

Exclusion criteria

Exclusion criteria: 1)Patients having past history of hypersensitivity to fosaprepitant 2)Used Pimozide

Design outcomes

Primary

Measure	Time frame
1)CTCAE ver.4.0 2)MAT	—

Secondary

Measure	Time frame
1)Questionnaire of convenience 2)Toxicity and side effect	—

Countries

Japan

Contacts

Public ContactAkihito Tsuji

Kobe City Medical Center General Hospital Department of Medical oncology

tsuji@kcho.jp078-302-4321

Outcome results